Description: Calprotectin, Human, ELISA kit
Calprotectin, also known as MRP-8/MRP-14 or S100A8/A9 heterocomplex, is formed out of the calcium-binding, migration inhibitory factor-related proteins, MRP-8 (S100A8) and MRP-14 (S100A9). The expression of these proteins is largely confined to the cytosol of neutrophils and monocytes. The complex formation of these proteins is calcium-dependent. Calprotectin comprises 60% of the cytoplasmic protein fraction of circulating polymorphonuclear granulocytes and is also found in monocytes, macrophages and ileal tissue eosinophils. Peripheral blood monocytes carry the antigen extra- and intracellularly, neutrophils only intracellularly. Calprotectin has antibacterial, antifungal, immunomodulating and antiproliferative effects. Furthermore, it is a potent chemotactic factor for neutrophils. Plasma concentrations are elevated in diseases associated with increased neutrophil activity. During intestinal wall inflammation, granulocytes transmigrate through the intestinal wall. Therefore calprotectin is also detectable in faeces. Several investigations report that faecal calprotectin is significantly increased in intestinal diseases such as inflammatory bowel disease (IBD), Crohn's disease, ulcerative colitis and colon cancer. Normal human plasma contains a calprotectin concentration ranging from ~100 to 3000 ng/ml.
Specifications
| Catalog number |
HK325-02 |
| Product type |
Assays |
| Quantity |
2 x 96 det. |
| Standard range |
1.6-100 ng/ml |
| Detection level |
1.6 ng/ml |
| Working volume |
100 µl/well |
| Species |
Human |
| Alias |
MRP-8/MRP-14, S100A8/S100A9 |
| Application |
The human calprotectin ELISA has been developed for the quantitative measurement of natural calprotectin heterodimer in plasma, cell culture medium, urine and faeces. |
| Disease |
Gastroenterology |
| Principle |
The human calprotectin ELISA is a ready-to-use solid-phase enzyme-linked immunosorbent assay based on the sandwich principle with a working time of 3½ hours.
The efficient format of a plate with twelve disposable 8-well strips allows free choice of batch size for the assay.
Samples and standards are captured by a solid bound specific antibody.
Biotinylated tracer antibody will bind to captured calprotectin.
Streptavidin-peroxidase conjugate will bind to the biotinylated tracer antibody.
Streptavidin-peroxidase conjugate will react with the substrate, tetramethylbenzidine (TMB).
The enzyme reaction is stopped by the addition of oxalic acid.
The absorbance at 450 nm is measured with a spectrophotometer. A standard curve is obtained by plotting the absorbance (linear) versus the corresponding concentrations of the calprotectin standards (log).
The human calprotectin concentration of samples, which are run concurrently with the standards, can be determined from the standard curve.
|
| Storage and Stability |
Product should be stored at 4 °C. Under recommended storage conditions, product is stable for one year. |
| Precautions |
For research use only. Not for use in or on humans or animals or for diagnostics. It is the responsibility of the user to comply with all local/state and Federal rules in the use of this product. Hycult Biotech is not responsible for any patent infringements that might result with the use of or derivation of this product. |
| References |
1. Peake, J et al; Systemic inflammatory responses to maximal versus submaximal
lengthening contractions of the elbow flexors. Exrc Immunol Rev 2006, 12: 72
2. Leclercq A et al; Involvement of intraplaque hemorrhage in atherothombosis evolution
via neutrophil protease enrichment. J Leukoc Biol 2007, 82: 1420
3. Martin-Ventura J et al ; Low plasma levels of HSP70 in patients with carotid
atherosclerosis are associated with increased levels of proteolytic markers of neutrophil
activation. Atherosclerosis 2007, 194: 334
4. Peake, J et al; Body temperature and its effect on leukocyte mobilization, cytokines and
markers of neutrophil activation during and after exercise. Eur J Appl Physiol 2008, 102:
391
5. Gecse, K et al; Increased faecal serine protease activity in diarrhoeic IBS patients: a
colonic luminal factor impairing colonic permeability and sensitivity. Gut 2009, 57: 591 |
|
